Stocks Telegraph

ABUS Stock Price History and Quote Analysis: Insights for Investors

NASDAQ:ABUS

Arbutus Biopharma Corporation

$4.31
-0.25-5.48%
At Close 4:00 PM
$4.30
-0.01-0.23%
Pre-Market 07:54 PM
71.67
BESG ScoreESG Rating

ABUS FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

ABUS Income Statement


A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

Date2024-06-302024-03-312023-12-312023-09-302023-06-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202320232023
periodQ2Q1Q4Q3Q2
revenue1.726M1.532M2.145M4.658M4.651M
cost of revenue356.00K355.00K359.00K369.00K342.00K
gross profit1.37M1.177M1.786M4.289M4.309M
gross profit ratio0.7940.7680.8330.9210.926
research and development expenses15.551M15.403M17.564M20.169M17.692M
general and administrative expenses7.547M5.312M5.101M5.842M5.98M
selling and marketing expenses-356.00K-355.00K-359.00K00
selling general and administrative expenses7.191M4.957M4.742M5.842M5.98M
other expenses211.00K180.00K0205.00K0
operating expenses22.742M20.36M22.306M26.216M23.672M
cost and expenses23.098M20.715M22.665M26.216M23.672M
interest income1.829M1.545M1.465M1.494M1.461M
interest expense34.00K44.00K44.00K-46.00K171.00K
depreciation and amortization356.00K355.00K359.00K369.00K342.00K
ebitda-21.016M-18.828M-20.161M-21.558M-17.218M
ebitda ratio-12.176-12.29-9.399-4.628-3.702
operating income-21.372M-19.183M-20.52M-21.558M-18.385M
operating income ratio-12.382-12.522-9.566-4.628-3.953
total other income expenses net1.576M1.308M1.208M1.454M637.00K
income before tax-19.796M-17.875M-19.312M-20.104M-17.094M
income before tax ratio-11.469-11.668-9.003-4.316-3.675
income tax expense-1.00-1.000-369.00K171.00K
net income-19.796M-17.875M-19.312M-20.104M-17.094M
net income ratio-11.469-11.668-9.003-4.316-3.675
eps-0.11-0.10-0.11-0.12-0.10
eps diluted-0.11-0.10-0.11-0.12-0.10
weighted average shs out188.041M175.626M168.436M167.513M166.063M
weighted average shs out dil188.041M175.626M168.436M167.513M166.063M
Graph

ABUS Balance Sheet


Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

Date2024-06-302024-03-312023-12-312023-09-302023-06-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202320232023
periodQ2Q1Q4Q3Q2
cash and cash equivalents62.788M43.101M26.285M17.531M27.197M
short term investments79.198M86.139M99.718M116.649M125.287M
cash and short term investments141.986M129.24M126.003M134.18M152.484M
net receivables2.067M2.739M2.376M7.427M2.614M
inventory-6.234M1.000-5.256M-2.614M
other current assets4.167M3.893M3.648M5.256M3.702M
total current assets148.22M135.872M132.027M141.607M158.80M
property plant equipment net5.296M5.741M6.09M6.535M6.955M
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments6.527M8.677M6.284M10.496M11.057M
tax assets00000
other non current assets0-1.0003.00K11.00K
total non current assets11.823M14.418M12.374M17.034M18.023M
other assets01.001.0000
total assets160.043M150.29M144.401M158.641M176.823M
account payables2.652M3.743M3.223M2.26M1.044M
short term debt453.00K502.00K425.00K412.00K397.00K
tax payables00000
deferred revenue11.034M11.547M11.791M12.106M15.327M
other current liabilities8.456M4.504M7.048M7.546M7.761M
total current liabilities22.595M20.296M22.487M22.324M24.529M
long term debt5.859M6.396M6.953M1.497M1.646M
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities9.135M8.961M8.943M15.483M15.955M
total non current liabilities14.994M15.357M15.896M16.98M17.601M
other liabilities00000
capital lease obligations1.144M1.181M1.343M1.909M2.043M
total liabilities37.589M35.653M38.383M39.304M42.13M
preferred stock00000
common stock1.403B1.377B1.35B1.346B1.344B
retained earnings-1.314B-1.295B-1.277B-1.257B-1.237B
accumulated other comprehensive income loss-48.308M-48.371M-48.421M-48.884M-49.468M
other total stockholders equity81.751M80.22M81.27M79.546M77.202M
total stockholders equity122.454M114.637M106.018M119.337M134.693M
total equity122.454M114.637M106.018M119.337M134.693M
total liabilities and stockholders equity160.043M150.29M144.401M158.641M176.823M
minority interest00000
total investments85.725M94.816M106.002M127.145M163.541M
total debt7.456M8.079M8.721M1.909M2.043M
net debt-55.332M-35.022M-17.564M-15.622M-25.154M
Graph

ABUS Cash Flow


A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

Date2024-06-302024-03-312023-12-312023-09-302023-06-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202320232023
periodQ2Q1Q4Q3Q2
deferred income tax00-1.495M-678.00K-534.00K
stock based compensation3.18M2.014M1.723M2.483M2.964M
change in working capital2.759M-2.859M1.735M-3.382M-4.004M
accounts receivables371.936K-363.00K402.281K443.00K50.00K
inventory002.00-1.00M-182.00K
accounts payables2.855M-2.024M543.276K1.00M-848.00K
other working capital-468.298K-472.00K789.37K-3.825M-3.024M
other non cash items-98.54K4.181M764.862K-472.00K-1.233M
net cash provided by operating activities-14.265M-19.295M-16.226M-21.784M-19.559M
investments in property plant and equipment-321.00-95.00K13.36K-32.00K-859.00K
acquisitions net037.186M-265.0020.084K-2.30M
purchases of investments-32.175M-25.397M-23.053M-7.085M-29.20M
sales maturities of investments41.852M37.186M44.685M17.526M31.50M
other investing activites9.734M458.00K1.00-84.002.30M
net cash used for investing activites9.677M11.694M21.645M10.429M1.441M
debt repayment00000
common stock issued24.025M24.43M3.417M1.396M4.742M
common stock repurchased00000
dividends paid00000
other financing activites24.37M24.43M0285.00K4.742M
net cash used provided by financing activities24.025M24.43M3.417M1.681M4.742M
effect of forex changes on cash-8.00K-13.00K14.00K8.00K-1.00K
net change in cash19.687M16.816M8.754M-9.666M-13.377M
cash at end of period62.788M43.101M26.285M17.531M27.197M
cash at beginning of period43.101M26.285M17.531M27.197M40.574M
operating cashflow-14.265M-19.295M-16.226M-21.784M-19.559M
capital expenditure-321.00-95.00K13.36K-32.00K-859.00K
free cash flow-14.265M-19.39M-16.212M-21.816M-20.418M
Graph

Frequently Asked Questions

How did Arbutus Biopharma Corporation do last quarter? What was its Total Revenue and Cost of Revenue?

A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, ABUS generated $1.73M in revenue last quarter, while its costs came in at $356.00K.

Last quarter, how much Gross Profit did Arbutus Biopharma Corporation report?

A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Arbutus Biopharma Corporation reported a $1.37M Gross Profit for the quarter ended Jun 30, 2024.

Have ABUS's Total Operating Expenses and Operating Income been favorable recently?

Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. ABUS incurred $22.74M worth of Operating Expenses, while it generated -$21.37M worth of Operating Income.

How much Net Income has ABUS posted recently?

The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Arbutus Biopharma Corporation, the company generated -$19.80M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.

At the end of the last quarter, how much Cash and Equivalents did Arbutus Biopharma Corporation have?

The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Arbutus Biopharma Corporation as of the end of the last quarter was $62.79M.

What are ABUS's Total Net Receivables for the last quarter?

Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, ABUS had Total Net Receivables of $2.07M.

In terms of Total Assets and Current Assets, where did Arbutus Biopharma Corporation stand at?

An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of ABUS were $148.22M, while the Total Assets stand at $160.04M.

As of the last quarter, how much Total Debt did Arbutus Biopharma Corporation have?

The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of ABUS's debt was $7.46M at the end of the last quarter.

What were ABUS's Total Liabilities during the last reported quarter?

A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, ABUS reported total liabilities of $37.59M.

How much did ABUS's Working Capital change over the last quarter?

Working Capital Change for ABUS was $2.76M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.

ABUS generated how much cash from operating activities?

An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. ABUS generated -$14.26M of Cash from Operating Activities during its recently reported quarter.

What was ABUS's latest reported Net Change in Cash?

An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. ABUS reported a $19.69M Net Change in Cash in the most recent quarter.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Log in to gain access to powerful insights powered by AI and Wallstreet analysts.

Login Form

OR
stockstelegraph

Join to access AI-powered insights from top Wall Street analysts.

Signup Form

OR
stockstelegraph

Log in to gain access to powerful insights powered by AI and Wallstreet analysts.

Reset Password Form

stockstelegraph

Subscribe to gain access to powerful insights powered by AI and Wallstreet analysts.

This feature is only available to Premium Users.

Subscribe Now